Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23786798 | 0.86 | ALOX15 (0.36) | ALOX15LMNAHSD17B10CYP2C19CYP1A2 | |
| Emylcamate SCHEMBL28554054 | 0.85 | TDP1 (0.36) | ALOX15LMNAHSD17B10CYP2C19CYP1A2 | |
| Emylcamate SCHEMBL28544576 | 0.85 | LMNA (0.39) | ALOX15LMNAHSD17B10CYP2C19CYP1A2 | |
| SCHEMBL23786745 | 0.84 | ALOX15 (0.34) | ALOX15LMNAHSD17B10CYP2C19CYP1A2 | |
| SCHEMBL9102210 | 0.81 | LMNA (0.36) | ALOX15LMNAHSD17B10TSHRCYP3A4 | |
| SCHEMBL27907896 | 0.80 | LMNA (0.52) | ALOX15LMNAHSD17B10TSHRCYP3A4 | |
| SCHEMBL30889169 | 0.79 | CYP1A2 (0.34) | ALOX15LMNAHSD17B10CYP2C19CYP1A2 | |
| SCHEMBL8435061 | 0.79 | ALOX15 (0.36) | ALOX15LMNAHSD17B10CYP2C19TSHR | |
| SCHEMBL11538247 | 0.79 | — | — | |
| SCHEMBL155686 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 479 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112782326-B | Method for simultaneously measuring fingerprint spectrum and multi-index component content of Weikangling capsule | 上海交通大学 | 2022-03-15 | — | — | CN | claimed |
| WO-2015072853-A1 | TREATMENT OF HERPES VIRUS INFECTION OUTBREAKS | RJG DEVELOPMENTS B.V. (NL) | 2015-05-21 | — | — | WO | claimed |
| WO-2015072852-A1 | TREATMENT OF HERPES VIRUS INFECTION OUTBREAKS USING VALERIAN | RJG DEVELOPMENTS B.V. (NL) | 2015-05-21 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8110569-B2 | Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-07 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2009018132-A9 | METHODS AND SYSTEMS FOR ATTENUATING THE TOLERANCE RESPONSE TO A DRUG | NEUROVISTA CORP (US) | 2009-06-25 | — | — | WO | claimed |
| WO-2009018132-A2 | METHODS AND SYSTEMS FOR ATTENUATING THE TOLERANCE RESPONSE TO A DRUG | NEUROVISTA CORPORATION (US) | 2009-02-05 | — | — | WO | claimed |
| US-20090030403-A1 | Methods and Systems for Attenuating the Tolerance Response to a Drug | CYBERONICS, INC. | 2009-01-29 | — | — | US | claimed |
| EP-2007741-A1 | ENANTIOMERICALLY PURE S-ETIFOXINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF THEIR USE | Xytis Inc. (US) | 2008-12-31 | — | — | EP | claimed |
| US-20080038331-A1 | Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use | ANVYL LLC | 2008-02-14 | — | — | US | claimed |
| WO-2007109288-A2 | ENANTIOMERICALLY PURE R-ETIFOXINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF THEIR USE | XYTIS INC. (US) | 2007-09-27 | — | — | WO | claimed |
| WO-2007109289-A1 | ENANTIOMERICALLY PURE S-ETIFOXINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF THEIR USE | XYTIS INC. (US) | 2007-09-27 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-4833265-A | DATB and its bis-urethan | TEXAS EXPLOSIVES CO INC (US) | 1989-05-23 | — | — | US | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080038331-A1 | Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use | PYGB, CYP2C9, CYP3A5 | ALOX15 1654/4885LMNA 3721/4885HSD17B10 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.